As LR-MDS patients have much lower rates of unfavorable karyotype or TET2, DNMT3A, and TP53 mutations, their treatment response is less likely to be influenced by cytogenetic or molecular abnormalities than that of their higher-risk counterparts. Here, DNMT3A is linked to myelodysplastic syndrome.